Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors Clinical Cancer Research, 05/06/2011
Rini BI et al.
–Axitinib efficacy correlated with dBP ≥90 mm Hg. Further investigation of dBP as a predictive biomarker of efficacy in patients receiving axitinib is warranted.
- Relationship between dBP ≥90 mm Hg and efficacy retrospectively explored across 5 phase II studies of single-agent axitinib for treatment of 4 different tumor types
- All patients had baseline BP ≤140/90 mm Hg and were stratified into 2 groups based upon in-clinic BP measurements after initiating therapy: those with dBP <90 mm Hg throughout therapy and those with at least one dBP ≥90 mm Hg
- mOS, mPFS, ORR, and AEs evaluated by dBP group in individual and pooled analyses
- 230 patients evaluated
- Patients with dBP ≥90 mm Hg had significantly longer mOS than those with dBP <90 mm Hg (30.1 versus 10.2 months; adjusted HR [95% CI] = 0.55; mPFS twofold longer in patients with dBP ≥90 mm Hg (13.1 versus 5.8 months; HR [95% CI] = 0.76 , and ORR was significantly higher (43.9% versus 12.0%)
- 8-week landmark analysis, mOS (25.8 versus 14.9 months) and mPFS (10.2 versus 7.1 months) were greater for patients in ≥90-mm Hg group
- AEssimilar between groups